CD274 and neoplasm: The upregulation of PD-L1 in surviving B16 tumor cells provides an opportunity to target this population using checkpoint inhibitors (anti-PD-L1) in combination with Ad.5-mda-7 to determine if this will enhance antitumor efficacy.